Literature DB >> 6406138

Levonorgestrel plasma levels during continuous administration with different models of subdermal implants.

F Alvarez, V Brache, A Faundes, E D Johansson, V Odlind, H Nash.   

Abstract

Plasma concentrations of levonorgestrel were determined in women using subdermal levonorgestrel implants. One group had 6 Silastic capsules (NORPLANT), one group had 4 and one group had 6 covered Silastic rods for variable lengths of time. Levonorgestrel concentrations remained constant around 0.4 ng/ml up until 6 years of use in the Norplant group. The observation period was shorter for the covered rods; plasma concentrations were, however, constant around 0.55 ng/ml and 0.70 ng/ml for 3.5 years with the 4 rods and 6 covered rods, respectively. The difference in mean levonorgestrel concentrations between the three groups were statistically significant (p less than 0.0005). Plasma levels of levonorgestrel were twice to three times higher in blood obtained from the arm with the implants compared to the levels found in the other arm. The application of a tourniquet for variable periods before blood sampling did not influence the plasma concentrations of levonorgestrel.

Entities:  

Keywords:  Comparative Studies; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Implants; Contraceptive Methods; Family Planning; Levonorgestrel; Reproductive Control Agents; Research Methodology; Studies

Mesh:

Substances:

Year:  1983        PMID: 6406138     DOI: 10.1016/0010-7824(83)90083-5

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  5 in total

1.  Facts about an implantable contraceptive: memorandum from a WHO meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

2.  [Concerning an implantable contraceptive: a memorandum of a WHO meeting].

Authors: 
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

3.  Comparison of plasma etonogestrel concentrations sampled from the contralateral-to-implant and ipsilateral-to-implant arms of contraceptive implant users.

Authors:  Alida M Gertz; Ian J Bishop; Boikhutso Simon; Kwana Lechiile; Opelo Badubi; Aamirah Mussa; Carolyn L Westhoff; Chelsea Morroni
Journal:  Contraception       Date:  2020-08-26       Impact factor: 3.375

Review 4.  Controlled-release delivery systems for hormones. A review of their properties and current therapeutic use.

Authors:  L R Beck; V Z Pope
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

Review 5.  Levonorgestrel. Clinical pharmacokinetics.

Authors:  K Fotherby
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.